# A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors

> **NCT00499499** · PHASE1 · SUSPENDED · sponsor: **Eisai Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** E7107

## Key facts

- **NCT ID:** NCT00499499
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2007-07
- **Primary completion:** 2009-06
- **Final completion:** 2010-08
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2009-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00499499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00499499, "A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00499499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*